An antibody against a CFTR-derived synthetic peptide, incorporated into living submandibular cells, inhibits beta-adrenergic stimulation of mucin secretion.
An antibody raised against a peptide in the first nucleotide-binding domain (NBD) of CFTR [1], incorporated into intact rat submandibular acini by hypotonic swelling, inhibited beta-adrenergic stimulated mucin secretion, without affecting cyclic AMP rise. The data are the first to show that a CFTR-antibody-containing cell results in defective stimulation of mucin secretion, as is seen in CF cells, and that this can be reversed by an excessive increase in cyclic AMP.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000032:analysis; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000032:analysis / Q000494:pharmacology; D003550:Cystic Fibrosis / Q000378:metabolism*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008565:Membrane Proteins / Q000276:immunology*; D009077:Mucins / Q000378:metabolism*; D010446:Peptide Fragments / Q000276:immunology; D051381:Rats; D013363:Submandibular Gland / Q000166:cytology / Q000187:drug effects*; D013873:Thionucleotides / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D000906:Antibodies; C505032:CFTR protein, human; D008565:Membrane Proteins; D009077:Mucins; D010446:Peptide Fragments; D013873:Thionucleotides; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C015929:8-((4-chlorophenyl)thio)cyclic-3',5'-AMP; D000255:Adenosine Triphosphate; D000242:Cyclic AMP; D007545:Isoproterenol; D015056:1-Methyl-3-isobutylxanthine